Purple Book reference family · 351(a) biologic
Measles, Mumps and Rubella Vaccine Live (PRIORIX)
Measles, Mumps and Rubella Vaccine Live is an FDA-licensed reference biologic from GlaxoSmithKline Biologicals.
351(a) biologicBLA 125748 GlaxoSmithKline Biologicals
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2022
Reference product
Originator biologic
351(a)BLA 125748
PRIORIX Measles, Mumps and Rubella Vaccine Live
GlaxoSmithKline Biologicals
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Measles, Mumps and Rubella Vaccine Live product.
4 yr 2 mo ago
Measles, Mumps and Rubella Vaccine Live: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Measles, Mumps and Rubella Vaccine Live.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
